文献速递白血病

欧洲白血病网2017急性髓系白血病风险分层:在风险适应方案中的验证

European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol.
PubMed 文献 · Blood Adv · 2022-01-01

该研究在Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12风险适应方案纳入的861例急性髓系白血病患者中回顾性验证欧洲白血病网2017(ELN 2017)风险分层:有利、中间、不良风险组分别327例(48%)、109例(16%)、245例(36%);2年和5年总生存率有利组为77%和70%,中间组为52%和46%,不良组为33%和23%;不良组内inv(3)/t(3;3)、复杂核型和/或TP53突变/17p异常亚组2年总生存率仅15%。

要点

  • ELN 2017有利、中间、不良风险组分别327例(48%)、109例(16%)、245例(36%)。
  • 2年总生存率有利组77%、中间组52%、不良组33%;5年分别为70%、46%、23%。
  • 不良组内inv(3)/t(3;3)、复杂核型和/或TP53突变/17p异常亚组2年总生存率15%。

核心结论

  • 本研究在按ELN 2017风险适应方案治疗的大队列中验证了ELN 2017风险分层,并识别出预后极差的遗传学亚组,该亚组需研究新策略。

研究设计与样本

  • 回顾性分析Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12风险适应方案纳入的861例急性髓系白血病患者。
  • 方案对ELN 2017有利风险组采用阿糖胞苷为基础的巩固治疗,对中间和不良风险组推荐异基因造血干细胞移植(alloSCT)作为缓解后策略。

主要发现

  • ELN 2017有利、中间、不良风险组分别327例(48%)、109例(16%)、245例(36%)。
  • 2年总生存率有利组77%、中间组52%、不良组33%;5年总生存率有利组70%、中间组46%、不良组23%。
  • 不良组内inv(3)/t(3;3)、复杂核型和/或TP53突变/17p异常亚组2年总生存率15%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The 2017 European LeukemiaNet (ELN 2017) guidelines for the diagnosis and management of acute myeloid leukemia (AML) have become fundamental guidelines to assess the prognosis and postremission therapy of patients. However, they have been retrospectively validated in few studies with patients included in different treatment protocols. We analyzed 861 patients included in the Cooperativo Para el Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias-12 risk-adapted protocol, which indicates cytarabine-based consolidation for patients allocated to the ELN 2017 favorable-risk group, whereas it recommends allogeneic stem cell transplantation (alloSCT) as a postremission strategy for the ELN 2017 intermediate- and adverse-risk groups. We retrospectively classified patients according to the ELN 2017, with 327 (48%), 109 (16%), and 245 (36%) patients allocated to the favorable-, intermediate-, and adverse-risk group, respectively. The 2- and 5-year overall survival (OS) rates were 77% and 70% for favorable-risk patients, 52% and 46% for intermediate-risk patients, and 33% and 23% for adverse-risk patients, respectively. Furthermore, we identified a subgroup of patients within the adverse group (inv(3)/t(3;3), complex karyotype, and/or TP53 mutation/17p abnormality) with a particularly poor outcome, with a 2-year OS of 15%. Our study validates the ELN 2017 risk stratification in a large cohort of patients treated with an ELN-2017 risk-adapted protocol based on alloSCT after remission for nonfavorable ELN subgroups and identifies a genetic subset with a very poor outcome that warrants investigation of novel strategies.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Bataller A, Garrido A, Guijarro F, et al. European LeukemiaNet 2017 risk stratification for acute myeloid leukemia: validation in a risk-adapted protocol. Blood Adv. 2022. PMID: 34911079. doi:10.1182/bloodadvances.2021005585

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。